ZA201406579B - Tetrahydro-quinazolinone derivates as tank and parp inhibitors - Google Patents

Tetrahydro-quinazolinone derivates as tank and parp inhibitors

Info

Publication number
ZA201406579B
ZA201406579B ZA2014/06579A ZA201406579A ZA201406579B ZA 201406579 B ZA201406579 B ZA 201406579B ZA 2014/06579 A ZA2014/06579 A ZA 2014/06579A ZA 201406579 A ZA201406579 A ZA 201406579A ZA 201406579 B ZA201406579 B ZA 201406579B
Authority
ZA
South Africa
Prior art keywords
quinazolinone
derivates
tetrahydro
tank
parp inhibitors
Prior art date
Application number
ZA2014/06579A
Other languages
English (en)
Inventor
Christina Esdar
Birgitta Leuthner
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201406579(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA201406579B publication Critical patent/ZA201406579B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2014/06579A 2012-02-09 2014-09-08 Tetrahydro-quinazolinone derivates as tank and parp inhibitors ZA201406579B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12000841 2012-02-09
PCT/EP2013/000078 WO2013117288A1 (en) 2012-02-09 2013-01-14 Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Publications (1)

Publication Number Publication Date
ZA201406579B true ZA201406579B (en) 2015-12-23

Family

ID=47628092

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/06579A ZA201406579B (en) 2012-02-09 2014-09-08 Tetrahydro-quinazolinone derivates as tank and parp inhibitors

Country Status (31)

Country Link
US (1) US9339503B2 (https=)
EP (1) EP2812323B1 (https=)
JP (1) JP6116592B2 (https=)
KR (1) KR20140121477A (https=)
CN (1) CN104093714B (https=)
AR (1) AR089944A1 (https=)
AU (1) AU2013218357B2 (https=)
BR (1) BR112014019357A8 (https=)
CA (1) CA2863991C (https=)
CL (1) CL2014002097A1 (https=)
CO (1) CO7020919A2 (https=)
DK (1) DK2812323T3 (https=)
EA (1) EA026611B1 (https=)
EC (1) ECSP14017586A (https=)
ES (1) ES2579980T3 (https=)
HR (1) HRP20160735T1 (https=)
HU (1) HUE029717T2 (https=)
IL (1) IL233984A (https=)
MX (1) MX349736B (https=)
NZ (1) NZ630170A (https=)
PE (1) PE20141823A1 (https=)
PH (1) PH12014501581A1 (https=)
PL (1) PL2812323T3 (https=)
PT (1) PT2812323T (https=)
RS (1) RS55377B1 (https=)
SG (1) SG11201404654SA (https=)
SI (1) SI2812323T1 (https=)
TW (1) TWI572593B (https=)
UA (1) UA116627C2 (https=)
WO (1) WO2013117288A1 (https=)
ZA (1) ZA201406579B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
BR112016008994A2 (pt) * 2013-11-07 2017-09-19 Lilly Co Eli Compostos de pirido[2,3-d]pirimidin-4-ona como inibidores de tanquirase
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018003962A1 (ja) 2016-06-30 2018-01-04 国立研究開発法人理化学研究所 新規化合物又はその薬理学的に許容される塩
CN108727302A (zh) * 2017-10-23 2018-11-02 科迈化工股份有限公司 一种环保型n-叔丁基-2-苯并噻唑次磺酰胺(ns)合成工艺
EP3733186B1 (en) 2017-12-27 2024-12-04 Japanese Foundation For Cancer Research Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
AU2019320945C1 (en) 2018-08-16 2021-09-30 F. Hoffmann-La Roche Ag Fused ring compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS019702A0 (en) * 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
ATE540936T1 (de) * 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
ES2359931T3 (es) 2005-03-11 2011-05-30 Merck Patent Gmbh Tetrahidro- y dihidroquinazolinonas.
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011111880A1 (ko) * 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물

Also Published As

Publication number Publication date
TW201336828A (zh) 2013-09-16
SI2812323T1 (sl) 2016-08-31
NZ630170A (en) 2016-03-31
CA2863991C (en) 2020-08-11
CN104093714B (zh) 2016-08-24
SG11201404654SA (en) 2014-09-26
CA2863991A1 (en) 2013-08-15
HUE029717T2 (en) 2017-03-28
AU2013218357A1 (en) 2014-09-25
EP2812323A1 (en) 2014-12-17
ECSP14017586A (es) 2015-09-30
US9339503B2 (en) 2016-05-17
EA026611B1 (ru) 2017-04-28
TWI572593B (zh) 2017-03-01
DK2812323T3 (en) 2016-05-09
HK1202551A1 (zh) 2015-10-02
WO2013117288A8 (en) 2014-07-31
PL2812323T3 (pl) 2016-09-30
PH12014501581B1 (en) 2014-10-08
IL233984A (en) 2017-09-28
MX349736B (es) 2017-08-10
UA116627C2 (uk) 2018-04-25
CO7020919A2 (es) 2014-08-11
US20150025071A1 (en) 2015-01-22
JP6116592B2 (ja) 2017-04-19
PH12014501581A1 (en) 2014-10-08
BR112014019357A2 (https=) 2017-06-20
AU2013218357A8 (en) 2015-01-22
EP2812323B1 (en) 2016-04-06
ES2579980T3 (es) 2016-08-18
AR089944A1 (es) 2014-10-01
CL2014002097A1 (es) 2014-11-07
EA201400879A1 (ru) 2015-01-30
HRP20160735T1 (hr) 2016-07-29
PE20141823A1 (es) 2014-11-29
RS55377B1 (sr) 2017-03-31
CN104093714A (zh) 2014-10-08
AU2013218357B2 (en) 2017-01-05
WO2013117288A1 (en) 2013-08-15
PT2812323T (pt) 2016-07-13
BR112014019357A8 (pt) 2017-07-11
MX2014009491A (es) 2014-08-29
KR20140121477A (ko) 2014-10-15
JP2015506965A (ja) 2015-03-05

Similar Documents

Publication Publication Date Title
ZA201406579B (en) Tetrahydro-quinazolinone derivates as tank and parp inhibitors
ZA201407554B (en) Dna-pk inhibitors
SI2882734T1 (sl) Dihidropiridon kot faktor XIA inhibitorji
IL237011A0 (en) Dihydropyridone p1 as factor xia inhibitors
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
SG11201501173SA (en) PI3Kδ INHIBITOR
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
IL236138A (en) Dipluoro-hexahydro-cyclophenoxazinyls and diplooro-hexahydro-benzooxazinyls as bace inhibitors1
IL235919A0 (en) inhibitors of fbxo3
EP2885291A4 (en) INHIBITORS OF VEGFR3
EP2885292A4 (en) VEGFR3 INHIBITORS
HUE038364T2 (hu) Random intraészterezés
EP2875208A4 (en) PLUG
PL2634424T3 (pl) Sposób budowania fundamentu dla konstrukcji podobnej do wieży
GB201203879D0 (en) Pack-a-truck trailer
GB201209483D0 (en) Spirit level and attachment
GB201207768D0 (en) Corrosion inhibitor